Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
79 hedge funds and large institutions have $157M invested in Unity Biotechnology in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 10 reducing their positions, and 5 closing their positions.
320% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 5
240% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 10
58% more capital invested
Capital invested by funds: $99.7M → $157M (+$57.5M)
25% more funds holding
Funds holding: 63 → 79 (+16)
0.96% more ownership
Funds ownership: 3.78% → 4.74% (+0.96%)
50% less call options, than puts
Call options by funds: $2K | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.38M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.47M |
| 3 |
Millennium Management
New York
|
+$1.32M |
| 4 |
BlackRock
New York
|
+$1.03M |
| 5 |
Morgan Stanley
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$314K |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$117K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$84K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$23.6K |
UBX Hedge Fund Activity: Q4 2019 in Review
79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2019, worth a combined $157M — up 58% from $99.7M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new UBX positions and 5 closed out — a net gain of 16 holders — while 34 added to existing stakes and 10 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $2.38M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $314K sold.
- 79 institutional investors held Unity Biotechnology (UBX) as of Q4 2019, up from 63 in Q3 2019.
- Funds reported $157M of Unity Biotechnology stock for Q4 2019, up 58% quarter-over-quarter.
- 21 funds opened new Unity Biotechnology positions in Q4 2019 and 5 closed out, a net change of +16 holders.
- The largest Unity Biotechnology buyer in Q4 2019 was Jacobs Levy Equity Management, an estimated $2.38M added.
- The largest Unity Biotechnology seller in Q4 2019 was EcoR1 Capital, an estimated $314K sold.
Based on aggregated 13F filings for Q4 2019.